Drug news
Aganocide (Novabay Pharma) enters Phase IIb trial for Adenoviral Conjunctivitis
NovaBay Pharmaceuticals, Inc. is developing its first-in-class, anti-infective Aganocide compounds for the local non-systemic treatment and prevention of infections.The company has announced that it has selected multiple organizations to manage the Company's Phase IIb clinical study of NVC-422 for the treatment of Adenoviral Conjunctivitis, a form of "pink eye." This global study is anticipated to enroll up to 450 patients with confirmed Adenoviral Conjunctivitis at investigational sites in India, Brazil, and the United States. The drug is also in Phase II trials for Impetigo
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.